These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

73 related items for PubMed ID: 3116548

  • 1. Results of long term treatment of advanced prostatic cancer with the LHRH analogue buserelin.
    Fontana D, Randone DF, Isaia GC, Colombo M, Giusti M, Bellina M, Rolle L, Fasolis G.
    Prog Clin Biol Res; 1987; 243A():239-41. PubMed ID: 3116548
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
    Labrie F, Dupont A, Belanger A, Lefebvre FA, Raynaud JP.
    J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
    [Abstract] [Full Text] [Related]

  • 5. Experience with an LHRH analogue in the management of relapsed progressive prostatic cancer.
    Kerle D, Williams G, Ware H, Doble A, Allen J, Bloom SR.
    Br J Urol; 1984 Oct; 56(5):495-8. PubMed ID: 6242022
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
    Debruyne FM, Karthaus HF, Schröder FH, de Voogt HJ, de Jong FH, Klijn JG.
    Prog Clin Biol Res; 1985 Oct; 185A():251-70. PubMed ID: 3929265
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Long-term endocrine profiles of prostatic carcinoma patients under pernasal as well as intramuscular Gn-RH analogue treatment.
    Wenderoth UK, Jacobi GH.
    Prog Clin Biol Res; 1985 Oct; 185A():297-305. PubMed ID: 3162176
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Preliminary report on a phase II multicentric study on depot LH-RH analogue in advanced prostatic cancer.
    Bono AV, Pozzi E, Bianco A, Morelli A, Bolgan A, Albano D, Frugoni A, Usai E.
    Prog Clin Biol Res; 1987 Oct; 243A():251-3. PubMed ID: 2958856
    [No Abstract] [Full Text] [Related]

  • 15. New treatment modalities in prostatic cancer: LHRH superagonists. Symposium held during the World Congress of Oncology. Budapest, Hungary, August 26, 1986.
    Am J Clin Oncol; 1988 Oct; 11 Suppl 1():S1-46. PubMed ID: 3133942
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Treatment of prostatic cancer with intranasal administration of LHRH analog, Buserelin (Hoe 766) study of the optimum dosage of intranasal application].
    Niijima T, Kishimoto T, Shimazaki J, Yoshida O, Isurugi K.
    Hinyokika Kiyo; 1988 Jul; 34(7):1309-19. PubMed ID: 3140622
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Drug information. Drug treatment can now replace castration in prostatic cancer].
    Dahlerup J.
    Sygeplejersken; 1986 Mar 26; 86(13-14):40, 41. PubMed ID: 3103250
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.